ENDRA Life Sciences Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated April 27, 2021, provides preliminary financial estimates for ENDRA Life Sciences Inc. for the quarter ended March 31, 2021. The Company is an emerging growth company incorporated in Delaware. The data presented is unaudited and subject to final adjustments upon completion of financial closing procedures.
Key Financial Metrics
- Revenue: $0 (Expected for Q1 2021; $0 for Q1 2020).
- Net Loss: Approximately $2.5 million for Q1 2021.
- Cash and Cash Equivalents: $16.8 million as of March 31, 2021.
- Profit Margins: Not applicable due to zero revenue.
- Debt and Liquidity: The filing does not provide specific debt figures or liquidity ratios beyond the cash balance.
Material Changes vs. Prior Period
Compared to the quarter ended March 31, 2020, the Company expects a reduction in its net loss. The estimated net loss for Q1 2021 is approximately $2.5 million, an improvement from the approximately $3.3 million net loss recorded in the same period of the prior year. Revenue remained at zero for both periods.
Outlook, Risks, and Unusual Items
The filing contains forward-looking statements regarding future plans and expectations, which are subject to risks and uncertainties. Management notes that the preliminary financial information is based on current estimates and has not been audited or reviewed by the independent registered public accounting firm. No specific guidance for future periods or unusual items were detailed beyond the preliminary loss estimate.
Investor Verification Checklist
- Verify the final audited net loss for Q1 2021 against the preliminary estimate of $2.5 million.
- Confirm the final cash balance of $16.8 million in the upcoming 10-Q filing.
- Review the upcoming 10-Q for details on operating expenses driving the net loss, as revenue remains non-existent.
- Monitor for any updates on the Company's cash burn rate and runway given the lack of revenue.